Neovascular Age-related Macular Degeneration Clinical Trial
Official title:
Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration and the Investigation on the Effect of Oral Probiotics as a Treatment - A Pilot Study
A pilot study for Associations between the oral and intestinal microbiome and neovascular age-related macular degeneration and the investigation on the effect of oral probiotics as a treatment The investigators recruit the neovascular AMD patients and control patients. 1. 15 neovascular AMD patients with anti-VEGF treatment and oral probiotics supplement 2. 15 neovascular AMD patients with anti-VEGF treatment and no oral probiotics supplement 3. 15 control patients and no oral probiotics supplement The investigators will collect stool, blood, and saliva sample at the baseline and 6 months, and analyze the oral and intestinal microbiome changes.
Status | Recruiting |
Enrollment | 45 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - Normal BMI patients - Diagnosed as neovascular AMD (experimental & sham group) - Normal patients (control group) Exclusion Criteria: - Obese (BMI > 30) - Past surgical history involving intestinal diseases - Previous oral antibiotic treatment before 1 week at the baseline enroll - Previous oral probiotics supplement - Previous ophthalmic retinal diseases except neovascular AMD |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Bundang Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Oral microbiome changes after oral probiotics supplement in neovascular AMD patients | The investigators will analyze the oral microbiome changes (baseline and 6 months after taking oral probiotics) in experimental, sham, and control groups.
Microbiome relative abundance changes in percentage (%) will be statistically analyzed between baseline and 6 months. |
6 months after enrollment | |
Primary | Intestinal microbiome changes after oral probiotics supplement in neovascular AMD patients | The investigators will analyze the intestinal microbiome changes (baseline and 6 months after taking oral probiotics) in experimental, sham, and control groups.
Microbiome relative abundance changes in percentage (%) will be statistically analyzed between baseline and 6 months. |
6 months after enrollment | |
Secondary | Visual acuity changes after oral probiotics supplement | If possible, visual acuity difference between experimental and sham group (oral probiotics vs. no oral probiotics) in the neovascular AMD patients.
Visual acuity will be measured by the ETDRS eye chart (scale : letters). |
6 months after enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101877 -
The Sahlgrenska Anti-VEGF Study
|
Phase 2 | |
Completed |
NCT03953079 -
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
|
Phase 2 | |
Terminated |
NCT03577899 -
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Completed |
NCT01926977 -
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT00370539 -
Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD
|
Phase 3 | |
Recruiting |
NCT03683251 -
Extension Study for the Port Delivery System With Ranibizumab (Portal)
|
Phase 3 | |
Completed |
NCT03909425 -
Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography
|
||
Completed |
NCT03744767 -
Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
Recruiting |
NCT04690556 -
Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD
|
Phase 3 | |
Completed |
NCT05281042 -
Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
|
||
Completed |
NCT03677934 -
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
|
Phase 3 | |
Recruiting |
NCT03594461 -
Intense Treatment Regimen With Intravitreal Aflibercept Injection
|
Phase 1/Phase 2 | |
Completed |
NCT05131646 -
Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
|
||
Completed |
NCT04537884 -
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
|
Phase 1 | |
Completed |
NCT03216538 -
Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Completed |
NCT04304755 -
Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)
|
Phase 2 | |
Completed |
NCT01958918 -
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
|
Phase 4 | |
Active, not recruiting |
NCT01918878 -
Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
|
Phase 4 | |
Completed |
NCT01712035 -
Neovascular Age-related Macular Degeneration
|